丰原药业
(000153)
| 流通市值：29.37亿 | | | 总市值：29.74亿 |
| 流通股本：4.59亿 | | | 总股本：4.65亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,671,360,364.24 | 835,922,413.31 | 3,858,212,108.59 | 3,125,145,826.83 |
| 营业收入 | 1,671,360,364.24 | 835,922,413.31 | 3,858,212,108.59 | 3,125,145,826.83 |
| 二、营业总成本 | 1,599,311,598.2 | 794,467,362.14 | 3,742,039,608.38 | 3,040,766,325.73 |
| 营业成本 | 1,297,339,647.06 | 644,507,248.31 | 3,149,318,256.09 | 2,578,139,649.75 |
| 税金及附加 | 15,779,244.81 | 8,151,724.79 | 33,423,714.06 | 25,365,320.75 |
| 销售费用 | 175,795,993.05 | 93,192,010.41 | 307,889,605.99 | 257,448,980.46 |
| 管理费用 | 77,104,050.97 | 36,535,776.13 | 170,158,246.68 | 112,081,625.15 |
| 研发费用 | 20,763,825.51 | 6,420,497.81 | 48,942,611.27 | 44,171,103.67 |
| 财务费用 | 12,528,836.8 | 5,660,104.69 | 32,307,174.29 | 23,559,645.95 |
| 其中:利息费用 | 15,124,339.38 | 7,290,456.22 | 35,201,477.98 | 26,007,397.71 |
| 其中:利息收入 | 3,252,138.7 | 2,007,056.72 | 3,067,029.18 | 2,781,556.44 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -5,965,593.5 | -120,190.23 | -2,650,611.03 | 1,470,294.35 |
| 加:投资收益 | 10,453,128.78 | - | 8,556,538.8 | 8,476,522.5 |
| 资产处置收益 | -808.33 | -808.33 | -326,419.46 | -170,721.19 |
| 资产减值损失(新) | -13,990,311.9 | -1,175,073.17 | -14,716,146.67 | -3,359,826.86 |
| 信用减值损失(新) | -2,984,869.49 | -2,607,905.77 | -18,699,392.25 | -5,277,746.31 |
| 其他收益 | 10,317,806.36 | 6,900,144.05 | 37,721,195.53 | 28,815,668.16 |
| 四、营业利润 | 69,878,117.96 | 44,451,217.72 | 126,057,665.13 | 114,333,691.75 |
| 加:营业外收入 | 5,395,331.08 | 260,965.65 | 8,258,029.8 | 1,390,641.98 |
| 减:营业外支出 | 577,381.32 | 276,754.61 | 9,136,080.52 | 1,774,358.29 |
| 五、利润总额 | 74,696,067.72 | 44,435,428.76 | 125,179,614.41 | 113,949,975.44 |
| 减:所得税费用 | 4,418,244.33 | 8,001,056.12 | 30,375,444.52 | 15,734,876.82 |
| 六、净利润 | 70,277,823.39 | 36,434,372.64 | 94,804,169.89 | 98,215,098.62 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 70,277,823.39 | 36,434,372.64 | 94,804,169.89 | 98,215,098.62 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 71,286,563.34 | 37,006,766.92 | 99,415,904.27 | 100,284,311.64 |
| 少数股东损益 | -1,008,739.95 | -572,394.28 | -4,611,734.38 | -2,069,213.02 |
| 扣除非经常损益后的净利润 | 63,862,068.93 | 31,160,691.35 | 76,433,958.51 | 74,915,110.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.08 | 0.21 | 0.22 |
| (二)稀释每股收益 | 0.15 | 0.08 | 0.21 | 0.22 |
| 八、其他综合收益 | 29,826,607.58 | 40,302,903.55 | 21,085,740.01 | 24,669,992.92 |
| 归属于母公司股东的其他综合收益 | 29,701,516.48 | 40,246,928.78 | 20,891,693.22 | 24,511,062.88 |
| 九、综合收益总额 | 100,104,430.97 | 76,737,276.19 | 115,889,909.9 | 122,885,091.54 |
| 归属于母公司股东的综合收益总额 | 100,988,079.82 | 77,253,695.7 | 120,307,597.49 | 124,795,374.52 |
| 归属于少数股东的综合收益总额 | -883,648.85 | -516,419.51 | -4,417,687.59 | -1,910,282.98 |
| 公告日期 | 2026-08-28 | 2026-04-29 | 2026-04-29 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |